Basal ganglia volume is strongly related to P3 event-related potential in premanifest Huntington's disease

European Journal of Neurology

Volumn 18, Issue 8, 2011, Pages 1105-1108

  Jurgens, C K ^a,b   van der Hiele, K ^a,c   Reijntjes, R H A M ^a   van de Wiel, L ^a,c   Witjes Ane M N W ^a,b   van der Grond, J ^a   Roos, R A C ^a   Middelkoop, H A M ^a,c   van Dijk, J G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Basal ganglia; Huntington's disease; P3; Premanifest

Indexed keywords

ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE COURSE; EVENT RELATED POTENTIAL; GLOBUS PALLIDUS; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; LATENT PERIOD; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; PRIORITY JOURNAL; PUTAMEN; RATING SCALE; SUSTAINED ATTENTION TO RESPONSE TASK;

ATROPHY; BASAL GANGLIA; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAPHY; EVENT-RELATED POTENTIALS, P300; HETEROZYGOTE; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REACTION TIME;

EID: 79960311622     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03309.x     Document Type: Article

References (17)

1. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009; 8: 791-801.
2. Jurgens CK, Wiel van de L, Es van ACGM, et al. Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease. J Neurol 2008; 255: 1785-1791.
3. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994; 117: 859-876.
4. Cardenas VA, Chao LL, Blumenfeld R, et al. Using automated morphometry to detect associations between ERP latency and structural brain MRI in normal adults. Hum Brain Mapp 2005; 25: 317-327.
5. Rektor I, Bares M, Kanovsky P, et al. Cognitive potentials in the basal ganglia-frontocortical circuits. An intracerebral recording study. Exp Brain Res 2004; 158: 289-301.
6. Rektor I, Kaiiovský P, Bares M, et al. A SEEG study of ERP in motor and premotor cortices and in the basal ganglia. Clin Neurophysiol 2003; 114: 463-471.
7. Hömberg V, Hefter H, Granseyer G, Strauss W, Lange H, Hennerici M. Event-related potentials in patients with Huntington's disease and relatives at risk in relation to detailed psychometry. Electroencephalogr Clin Neurophysiol 1986; 63: 552-569.
8. Rosenberg C, Nudleman K, Starr A. Cognitive evoked potentials (P300) in early Huntington's disease. Arch Neurol 1985; 42: 984-987.
9. de Tommaso M, Sciruicchio V, Specchio N, et al. Early modifications of auditory event-related potentials in carriers of the Huntington's disease gene. Acta Neurol Belg 2003; 103: 192-198.
10. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136-142.
11. van der Hiele HK, Jurgens CK, Vein AA, et al. Memory activation reveals abnormal EEG in preclinical Huntington's disease. Mov Disord 2007; 22: 690-695.
12. Jurgens CK, Bos R, Luyendijk J, et al. Magnetisation transfer imaging in 'premanifest' Huntington's disease. J Neurol 2010; 257: 426-432.
13. Robertson IH, Manly T, Andrade J, Baddeley BT, Yiend J. Oops!': performance correlates of everyday attentional failures in traumatic brain injured and normal subjects. Neuropsychologia 1997; 35: 747-758.
14. Zordan L, Sarlo M, Stablum F. ERP components activated by the "Go" and "Withold!" conflict in the random sustained attention to response task. Brain Cogn 2008; 66: 57-64.
15. Thompson JC, Poliakoff E, Sollom AC, Craufurd D, Snowden S. Automaticity and attention in Huntington's disease: when two hands are not better than one. Neuropsychologia 2010; 48: 171-178.
16. Beste C, Saft C, Andrich J, Gold R, Falkenstein M. Response inhibition in Huntington's disease-a study using ERPs and sLORETA. Neuropsychologia 2008; 46: 1290-1297.
17. Beste C, Willemssen R, Saft C, Falkenstein M. Response inhibition subprocesses and dopaminergic pathways: basal ganglia disease effects. Neuropsychologia 2010; 48: 366-373.